Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

Shannon Puhalla1 Department of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PACorrespondence[email protected]

Sharon Wilks2 Department of Hematology Oncology, US Oncology-Cancer Care Centers of South Texas, San Antonio, TX

Adam M Brufsky1 Department of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA

Joyce O’Shaughnessy3 Department of Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX

Lee S Schwartzberg4 Department of Hematology/Oncology, West Cancer Center, University of Tennessee Health Science Center, Memphis, TN

Erhan Berrak5 Department of Medical Affairs, Formerly of Eisai Inc., Woodcliff Lake, NJ

James Song5 Department of Medical Affairs, Formerly of Eisai Inc., Woodcliff Lake, NJ

Linda Vahdat6 Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Your download is now in progress and you may close this window